MaxCyte Partners with TG Therapeutics for Innovative Therapies
MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a prominent company specializing in cell-engineering technologies, has entered into an exciting strategic platform license (SPL) with TG Therapeutics. This collaboration aims to push forward the development of groundbreaking treatments for autoimmune diseases, utilizing MaxCyte’s advanced Flow Electroporation technology and ExPERT™ platform.
Understanding the Collaboration
The agreement allows TG Therapeutics to access non-exclusive rights for research, clinical, and commercial use of MaxCyte’s innovative technologies. This partnership is poised to enhance TG Therapeutics' efforts to advance their novel therapies for B-cell diseases and to address unmet medical needs in the autoimmune therapeutic landscape.
About TG Therapeutics and Their Approach
TG Therapeutics is a fully integrated biopharmaceutical company focused on developing novel treatments aimed at B-cell diseases. They recently gained a significant asset through their acquisition of Precision BioSciences’ investigational allogeneic CD19 CAR T cell therapy, known as Azercabtagene Zapreleucel (azer-cel). With FDA clearance for an Investigational New Drug (IND) application, TG is gearing up to initiate a Phase 1 clinical trial for azer-cel, specifically targeting progressive multiple sclerosis (MS).
MaxCyte's Role in the Journey
Maher Masoud, President and CEO of MaxCyte, shared insights into the essential role their technology plays in advancing immunotherapy developments. The company’s cell-engineering technology provides a robust foundation for manufacturing T cell therapies, ensuring efficiency and effectiveness. MaxCyte’s seamless technology transfer capabilities have made it possible for TG Therapeutics to quickly adapt and integrate these powerful tools.
Innovations Driving the Future of Autoimmune Therapies
The ExPERT™ platform from MaxCyte represents the next generation of electroporation technology, enabling high transfection efficiency and cell viability. This state-of-the-art instrument portfolio is tailored for complex and scalable cell engineering, allowing researchers and companies to meet the demands of expanding biologics markets.
MaxCyte: Committed to Advancing Cell Engineering
With over 25 years of expertise, MaxCyte is committed to advancing the potential of cell therapies. Their operations encompass the complete continuum of cell therapy development from initial discovery to commercialization. As part of their dedication, they offer substantial technical, scientific, and regulatory support to all their partners.
Future Prospects
This partnership promises not only to enhance the therapeutic options for autoimmune diseases but also to set a broader benchmark for future collaborations within the biopharmaceutical industry. As both companies work closely together, they embody a united front in the mission to innovate and deliver vital treatments that improve patient outcomes worldwide.
Frequently Asked Questions
What technologies are involved in the MaxCyte and TG Therapeutics partnership?
The collaboration utilizes MaxCyte’s Flow Electroporation technology and ExPERT™ platform to develop advanced cell-based therapies.
What is the focus of TG Therapeutics’ research pipeline?
TG Therapeutics is focused on developing novel treatments for B-cell diseases, particularly autoimmune conditions and oncology.
How does the ExPERT™ platform benefit cell therapy development?
The ExPERT™ platform enhances transfection efficiency, cell viability, and allows for seamless scalability in cell engineering.
When is TG Therapeutics planning to begin their Phase 1 trial for azer-cel?
They are targeting the commencement of the Phase 1 trial for azer-cel in the upcoming future.
How can interested parties learn more about MaxCyte and TG Therapeutics?
More information is available on their respective websites and through investor relations contacts for detailed inquiries.
